Tanja Obradovic

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Tanja Obradovic
Jun 24, 2025, 05:53 | Blog
Tanja Obradovic: Teva Pharmaceuticals and Fosun Pharma Partnership on Anti-PD1-IL2 Immunotherapy
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Getting…
Jun 21, 2025, 16:22 | Blog
Tanja Obradovic: Can We Expect Rapid Arrival to the Bedside of the First in Class B7-H3-Directed Antibody Drug Conjugate?
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on Linkedin: "Can…
Jun 20, 2025, 22:51 | Blog
Tanja Obradovic on FDA Approval for Pfizer’s Talzenna with Xtandi in HRR-Mutated mCRPC
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Just…
Jun 1, 2025, 02:34 | Blog
Tanja Obradovic: HARMONi Trial - Topline Results Reveal Positive PFS for Ivonescimab in NSCLC
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "High…
May 28, 2025, 16:43 | Blog
Tanja Obradovic Highlights Positive ASCENT-03 Results for Trodelvy Ahead of ASCO 2025
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "ASCO2025…
May 21, 2025, 17:12 | Insight
Tanja Obradovic: Issue of Trial Data Applicability to US Patient Population is Resurfacing Again at FDA
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Issue…
May 16, 2025, 02:19 | Blog
Tanja Obradovic Highlights KEYNOTE-B96 Phase 3 Success in Ovarian Cancer
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, posted on LinkedIn: "Outstanding achievement today…
May 14, 2025, 13:48 | Blog
FDA's 'Project Interface' to provide outreach and engagement
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
May 13, 2025, 17:33 | Insight
Tanja Obradovic: AI Advancing Novel Cancer Drug Design and Patient Outcomes
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Great…
May 12, 2025, 04:43 | Insight
Tanja Obradovic: Final analysis of the randomized phase 2 part of the ASPEN-06 study of evorpacept
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Final…
May 10, 2025, 15:49 | Opinion
Tanja Obradovic Highlights FDA's input and critical role in advancing cell therapy field
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post by Friends of…
May 9, 2025, 11:28 | Blog
Tanja Obradovic Highlights Ivonescimab’s Phase III Entry in Pancreatic Cancer
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, posted on LinkedIn: "New frontier is…
Apr 27, 2025, 03:49 | Blog
Tanja Obradovic: Looking forward to insightful discussion at Next-Generation Therapies Meeting
Tanja Obradovic,  Oncology Medical Strategy Advisor at Mercurial AI, shared a post by Friends of…
Apr 25, 2025, 20:03 | Insight
Tanja Obradovic: Pharmaceutical innovation in oncology during economic unknowns and challenge to do better
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Pharmaceutical…
Apr 24, 2025, 10:39 | Blog
Tanja Obradovic: Improved PFS versus current SOC of taxane, trastuzumab and pertuzumab
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Apr 23, 2025, 20:29 | Blog
Tanja Obradovic: Just announced - Trodelvy in combination with Keytruda
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn: "Just announced -…
Apr 23, 2025, 11:43 | Blog
Critical challenges in cell therapy development - Friends of Cancer Research
Friends of Cancer Research shared a post on LinkedIn: "Speakers Announced! Friends of Cancer Research and…
Apr 18, 2025, 13:54 | Blog
Tanja Obradovic: Novel cell therapy is entering clinical development space
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Novel cell…
Apr 18, 2025, 13:07 | Blog
Tanja Obradovic: Even rougher times ahead for Biotech?
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Even…
Apr 18, 2025, 12:54 | Blog
Adam Fein: New on Drug Channels - who really controls specialty drug dispensing?
Adam Fein, President at Drug Channels Institute, an HMP Global company, shared a post on…
Apr 17, 2025, 12:45 | Drugs
Tanja Obradovic: New developments in the frontline treatment of Metastatic Hepatocellular Carcinoma
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn: "Movements in the 1st…
Apr 16, 2025, 17:03 | Blog
Tanja Obradovic: Another bevacizumab biosimilar entered the U.S. market
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn: "Just a few…
Mar 24, 2025, 18:22 | Insight
Tanja Obradovic: A novel mechanism for first-line melanoma patients is going to be explored by Eikon Therapeutics
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Since…
Mar 15, 2025, 16:53 | Science
Tanja Obradovic: Advancing repurposing of approved drugs with Avapritinib for high-grade glioma
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn about…
Mar 13, 2025, 08:31 | Blog
Tanja Obradovic: Turmoil within the Biotech sector continues as financing remains a challenge
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…
Mar 12, 2025, 12:04 | Blog
Tanja Obradovic about the Growing Importance of Strategic Program and Pipeline Management in Pharma
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn: "Strategic…
Feb 27, 2025, 10:03 | Blog
Tanja Obradovic: New option of immunotherapy for HNSCC is on the horizon
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…
Feb 18, 2025, 14:44 | Blog
Tanja Obradovic: Another step in the global move toward value-based therapeutic options
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn by…
Feb 15, 2025, 16:26 | Blog
International Childhood Cancer Day 2025
International Childhood Cancer Day (ICCD), February 15, calls to action to raise awareness about childhood cancer and…
Feb 10, 2025, 10:52 | Insight
Tanja Obradovic: How current FDA policy can affect advances in AI
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn about…
Feb 5, 2025, 00:03 | Blog
Tanja Obradovic: How Biotech companies approach oncology drug development and pipeline building/management
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn: "Possible tectonic shifts coming…
Jan 31, 2025, 19:25 | Insight
Tanja Obradovic: New Phase III trial with an innovative MOA may soon change the standard of care for second-line MSS CRC
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "New…
Jan 27, 2025, 14:40 | Blog
Tanja Obradovic: Lessons from 2024 for successful oncology drug development strategy
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "What…
Jan 27, 2025, 08:47 | Blog
Tanja Obradovic: Are we to see a major improvement in treatment options for glioblastoma patients?
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Are…
Nov 17, 2024, 07:43 | Blog
Tanja Obradovic: Important milestone for Dizal Pharmaceutical with sunvozertinib NDA submission
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Nov 11, 2024, 15:46 | Blog
Tanja Obradovic: New treatment option for patients with low PDL-1 expression in head and neck cancers
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…
Nov 2, 2024, 17:37 | Blog
How to Foster the Next Innovation in Oncology Clinical Development and Medical Affairs Strategy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post by…
Oct 14, 2024, 12:57 | Blog
Tanja Obradovic: Genenta Science announces opening of the Temferon trial in mRCC
Tanja Obradovic shared a post on LinkedIn: ''Clinical development landscape in metastatic renal cell carcinoma…
Oct 9, 2024, 15:40 | Blog
Tanja Obradovic: Orum Therapeutics is focusing its innovation pipeline on degrader-antibody conjugates
Tanja Obradovic shared a post on LinkedIn: "Great news from Orum Therapeutics, a Korea based biotech…
Oct 8, 2024, 11:35 | Insight
Pathways of drug development in Oncology specifically looking into time and nature of initial FDA approval, summarised by Tanja Obradovic
Tanja Obradovic shared a post on LinkedIn: "Insightful article just published by authors from National Pharmaceutical…
Oct 5, 2024, 08:24 | Insight
Tanja Obradovic: New Treatment for NSCLC Patients Targeting cMet Over-Expression
Tanja Obradovic shared a post on LinkedIn: "Novel antibody-drug conjugate (ADC) may be coming for…
Oct 4, 2024, 15:19 | Blog
Tanja Obradovic: FDA granted approval to selpercatinib for advanced or metastatic medullary thyroid cancer with a RET mutation
Tanja Obradovic shared a post on LinkedIn: "Outstanding news for patients with metastatic medulary thyroid…
Oct 3, 2024, 07:22 | Blog
Tanja Obradovic: AbbVie submitted telisotuzumab vedotin in adult NSCLC patients with tumors with EGFR non squamous histology
Tanja Obradovic shared a post on LinkedIn: "Completely new treatment option by novel antibody-drug conjugate (ADC)…
Oct 2, 2024, 15:39 | Blog
Tanja Obradovic: FDA ODAC's decision on PD-1 Inhibitors in HER2- Negative Gastric Cancer
Tanja Obradovic shared a post on LinkedIn: "In highly anticipated discussion on September 26th FDA Oncologic Drugs…
Oct 2, 2024, 08:24 | Blog
Tanja Obradovic: FDA just approved Osimertinib for adult patients with locally advanced, unresectable non-small cell lung cancer
Tanja Obradovic shared a post on LinkedIn: ''FDA just approved Osimertinib (Tagrisso), a third-generation EGFR-directed…
Sep 30, 2024, 08:39 | Opinion
Tanja Obradovic: Strategy of clinical development in oncology requires global considerations
Tanja Obradovic shared the following on LinkedIn: “Strategy of clinical development in oncology always encompasses…
Sep 28, 2024, 16:12 | Blog
Tanja Obradovic: AACR issues Cancer Progress Report 2024 with a focus on young adults and children
Tanja Obradovic shared the following on LinkedIn: “AACR just issued Cancer Progress Report 2024, which…
Sep 28, 2024, 08:32 | Blog
Tanja Obradovic: In order to achieve true breakthroughs in cancer therapy strong science needs to be accompanied with "thinking outside of the box"
Tanja Obradovic shared a post on LinkedIn: "As with everything road to successful drug development in…
Sep 25, 2024, 18:29 | Insight
Tanja Obradovic: Ligufalimab plus ivonescimab combined with chemo in the first-line CRC patients
Tanja Obradovic shared a post on LinkedIn: "Tackling large medical need in microsatellite stable (MSS)…
Sep 14, 2024, 10:51 | Blog
Tanja Obradovic: PIONeeR Project results will be presented at ESMO 2024 Presidential Symposium
Tanja Obradovic shared on LinkedIn: "Just announced that exciting results will be presented at ESMO…
Sep 10, 2024, 05:08 | Blog
Tanja Obradovic: Two practice-changing trials of Keytruda within Presidential Symposium of ESMO24
Tanja Obradovic shared on LinkedIn: "ESMO 2024 will have two practice-changing trials of Keytruda (Pembrolizumab)…
Aug 31, 2024, 16:56 | Blog
Tanja Obradovic: GI INNOVATION announced collaboration with Merck
Tanja Obradovic shared a post on LinkedIn: "Tackling challenges of cancer patients treatment after they progressed…
Aug 28, 2024, 17:09 | Blog
Tanja Obradovic: Importance of vigilant toxicity monitoring
Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…
Aug 26, 2024, 21:42 | Blog
Tanja Obradovic: Interesting update at ESMO 2024 on cancer-induced cachexia as PhII trial of ponsegromab
Tanja Obradovic posted on LinkedIn: “Interesting update will come at ESMO 2024 on possible option…
Aug 26, 2024, 21:24 | Blog
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC
Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…
Aug 26, 2024, 20:20 | Blog
Tanja Obradovic: Some points of interest from the Relativity-104 study
Tanja Obradovic shared on LinkedIn: "Opdualag, a cocktail of anti Lag-3 (relatlimab) and anti PD1…
Aug 26, 2024, 20:15 | Blog
Meta analysis of Immune checkpoint inhibitor induced cardiotoxicity
Tanja Obradovic shared on LinkedIn: "Important article reporting outstanding work of systematic review and meta analysis…
Aug 26, 2024, 19:50 | Blog
Tanja Obradovic reflects on first KRAS G12C mutation inhibitor approval
Tanja Obradovic posted on LinkedIn: "First KRAS G12C mutation inhibitor just got approval in China.…
Aug 2, 2024, 12:59 | Blog
Aleksandar Obradovic: I have been nominated for the 2024 USERN Prize for junior scientists in Medical Sciences
Aleksandar Obradovic, MD/PhD at Columbia University, shared a post on LinkedIn: ''I have been nominated…
Jul 6, 2024, 07:58 | Drugs
Tanja Obradovic: Important lesson in development of the PDL-1 inhibitor just came in
Tanja Obradovic posted on LinkedIn: "Important lesson in the development of the PDL-1 inhibitor just…
Jul 6, 2024, 05:13 | Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jul 2, 2024, 04:25 | OncoDaily Pulse
OncoDaily Party and Yvonne Award 2024 Photos - Part 2
On May 31st, 2024, during the ASCO Annual Meeting in Chicago, OncoDaily hosted the inaugural…
Jun 27, 2024, 02:53 | Blog
Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat
Tanja Obradovic shared on LinkedIn: . “Are we to expect completely new mechanism of action…
Jun 24, 2024, 15:49 | Insight
Tanja Obradovic: The landscape of targeting KRAS mutations just got busier
Tanja Obradovic shared on LinkedIn:          . "The landscape of KRAS mutations…
Jun 13, 2024, 13:21 | Drugs
Tanja Obradovic: How prevalent are policies that mandate step therapy for cancer drugs in the US?
Tanja Obradovic shared on LinkedIn: "How prevalent are health plan policies that mandate step therapy…
Jun 11, 2024, 06:28 | Blog
Tanja Obradovic: Intriguing results reported at ASCO24
Tanja Obradovic shared a post on LinkedIn: ''What about intriguing results reported at ASCO24? One…
Jun 4, 2024, 13:13 | Insight
Tanja Obradovic: NADINA trial making history at ASCO2024 plenary session
Tanja Obradovic shared on LinkedIn:   . "NADINA trial making history today at ASCO2024 plenary session.…
Jun 3, 2024, 15:25 | Societies
15 Posts From ASCO24 Day 3 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 3, 2024, 11:57 | Societies
Tanja Obradovic: Very dynamic day at ASCO2024
Tanja Obradovic shared a post on LinkedIn: "Very dynamic ASCO2024 day as we learned quite…
Jun 1, 2024, 00:00 | Blog
Tanja Obradovic: Gursel Aktan and Merck women's cancer team on just released positive OS data on KN 522
Tanja Obradovic shared a post on LinkedIn: "Congratulations to amazing leader in immunooncology drug development Gursel…
May 24, 2024, 01:22 | Blog
Tanja Obradovic on Radiopharmaceuticals in oncology
Tanja Obradovic shared a post on LinkedIn: "Radiopharmaceuticals in oncology have been recently very active clinical…
May 22, 2024, 08:39 | Blog
Tanja Obradovic: ASCO just published guidelines for germline genetic testing panels
Tanja Obradovic shared on LinkedIn: "Great service to public and oncology community as ASCO just published…
May 22, 2024, 03:53 | Drugs
Tanja Obradovic: FDA just announced withdrawal of the approval for BridgeBio Pharma Truseltiq
Tanja Obradovic shared a post on LinkedIn: “FDA just announced withdrawal of the approval for BridgeBio…
May 22, 2024, 02:47 | Insight
Visit ICON plc at ASCO24, booth 30119 to learn about One Search - ICON plc
Tanja Obradovic shared a post by ICON plc on LinkedIn, adding: “ASCO204 is almost to start.…
May 21, 2024, 00:56 | Blog
Tanja Obradovic: Carisma Therapeutics just announced that first cancer patient with solid tumor received CAR-monocyte
Tanja Obradovic shared a post on LinkedIn: ''As of yesterday new cell therapy modality may be…
May 20, 2024, 02:15 | Insight
Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy
Tanja Obradovic shared on LinkedIn: "Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1…
May 15, 2024, 09:38 | Blog
Tanja Obradovic: Important PDUFA on June 12th is coming up
Tanja Obradovic shared a post on LinkedIn: "Important PDUFA on June 12th is coming up that…
May 15, 2024, 08:32 | Blog
Tanja Obradovic: Private Biotech investment is on the steady rise reaching $3.1 billion in April
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON, shared on LinkedIn: “Private Biotech investment is…
May 15, 2024, 04:12 | Blog
Tanja Obradovic: News about effectiveness of PD-1 inhibitors in endometrial cancer continues to paint complex picture
Tanja Obradovic shared on LinkedIn: ''News about effectiveness of PD-1 inhibitors in endometrial cancer continues…
May 14, 2024, 11:07 | Blog
Tanja Obradovic: At ASCO 2024 at the ICON plc booth we share thoughts on latest in cancer treatment innovation
Tanja Obradovic shared a post by ICON plc on LinkedIn, adding: ''This year we are certain…
May 12, 2024, 07:27 | Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
May 3, 2024, 23:43 | Blog
Tanja Obradovic: All eyes are on ADCs coming from China's biotech innovation engine and CAR-T cell therapy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on…
May 3, 2024, 04:53 | Blog
Tanja Obradovic: Herceptin biosimilar Hercessi has just been approved by FDA
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on LinkedIn:…
May 2, 2024, 15:46 | Insight
Tanja Obradovic: Battle with breast cancer is raging
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON, shared on LinkedIn: "Battle with breast…
May 2, 2024, 15:25 | Blog
Tanja Obradovic: Interesting updates will be coming on ASCO 2024
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON, shared on LinkedIn: "ASCO 2024 is almost…
May 1, 2024, 10:55 | Blog
Tanja Obradovic: The spotlight of FDA last week
Tanja Obradovic, Vice President of  Oncology Scientific Affairs at ICON plc., shared a post on LinkedIn:…
May 1, 2024, 09:57 | Drugs
Tanja Obradovic: Dostarlimab chemotherapy in primary advanced or recurrent endometrial cancer
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON, shared on LinkedIn: "Further inroads of…
Apr 28, 2024, 18:45 | Blog
Tanja Obradovic: Absolutely great meeting and productive exchange around trends and needs in today's pharma world
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared a post by Why Summits…
Apr 20, 2024, 08:16 | Blog
Tanja Obradovic: One exciting novel approach is just about to enter clinical development
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn: "Cell…
Apr 17, 2024, 17:56 | Blog
Tanja Obradovic: When during clinical development Medical Affairs Strategy should be started with the full force? Join for dialog and my presentation
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn:…
Apr 17, 2024, 11:33 | Drugs
Tanja Obradovic: What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab?
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “What…
Apr 13, 2024, 07:17 | Blog
Tanja Obradovic: Exploring the Potential of B Cell Activation in Cancer Immunotherapy: Insights from AT-1965 Phase 1/2 Study
Tanja Obradovic, Vice President of Scientific Affairs at ICON plc., shared a post on LinkedIn: "In fighting cancer…
Apr 12, 2024, 17:18 | Drugs
Tanja Obradovic: Interesting statistics on the nature of licensing deals in pharmaceutics during last year
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “Interesting…
Apr 12, 2024, 16:43 | Drugs
Tanja Obradovic: Exciting new vaccine is about to start Phase III in advanced NSCLC patients that progressed following immunotherapy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “Exciting…
Apr 12, 2024, 05:16 | Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Mar 10, 2024, 20:14 | Blog
Tanja Obradovic: Access24 meeting was outstanding gathering of experts across product value aspects
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON plc, Medical Affairs, shared a post on…
Feb 17, 2024, 16:27 | Drugs
Tanja Obradovic: BioXcel Therapeutics received Fast Track designation by the FDA for BXCL701
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "Biotech companies…
Jan 31, 2024, 23:59 | Insight
Tanja Obradovic: Outstanding work from UK
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post by…
Jan 24, 2024, 08:04 | Blog
Tanja Obradovic: Clinical development includes the need to have critical focus on inclusion and diversity
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post by…
Dec 21, 2023, 10:06 | Blog
Tanja Obradovic: Asia Biotech companies are driving major advances in oncology this year
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, posted on LinkedIn: "Asia…
All: 100 Posts: 1 - 100
Special Coverage